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Sentinel lymph node biopsy (SLNB) is the standard surgical procedure for the axilla in early node-
negative breast cancer. To date, the “gold standard” to localize the sentinel lymph node (SLN) is the
radiotracer 99mTc with or without blue dye. The aim of this study was to evaluate potential equivalency of
the new SentiMag technique in comparison to the “gold standard”. Within this prospective, multi-
centric and multinational non-inferiority study including 150 patients 99mTc was compared with the
magnetic technique, using superparamagnetic iron oxide particles (SPIOs, Siennaþ) for localization of
SLNs. The results showed a detection rate per patient of 97.3% (146/150) for 99mTc vs. 98.0% (147/150) for
Siennaþ with a similar average number of removed SLNs per patient and a higher per patient malig-
nancy detection rate for the SPIO tracer. We obtained convincing results that magnetic SLNB can be
performed easily, safely and equivalently well in comparison to the radiotracer method.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Sentinel lymph node biopsy (SLNB) is widely accepted and has
replaced primary axillary lymph node dissection as the staging
procedure for early node-negative breast cancer. In 1994, Giuliano
et al. [1] performed SLNB by injecting isosulphan blue dye around
the tumour. In parallel, Krag et al. [2] and Veronesi et al. [3]
introduced the use of a radioactive tracer, technetium-99m
labelled nanocolloid (99mTc) and a hand-held gamma probe for
SLN detection. To date, the “gold standard” to detect the sentinel
lymph node (SLN) is the radiotracer alone, or in combination with
blue dye [4,5].
However, there are drawbacks connected to the combination
technique, such as radiation exposure of patients and healthcare
personnel, strong legislative control, limitations in radiotracery and Obstetrics, Agaplesion
rankfurt am Main, Germany.
3.
r Ltd. Open access under CC BY-NC-Navailability, dependency on nuclear medicine units and allergic
reactions to blue dye, which demonstrate a clinical need for new
radiation-free but accurate methods for SLN localization.
In this study we used a handheld magnetometer (SentiMag)
to detect the magnetic response from iron oxide particles trapped
in SLNs and a hand-held gamma probe to detect the 99mTc
radiotracer in a parallel manner. As magnetic tracer we used
Siennaþ, which is a superparamagnetic iron oxide (SPIO) com-
pound, originally developed for contrast-enhanced magnetic
resonance imaging. The aim of our study was to investigate the
potential equivalency of the SentiMag technique in comparison
to the “gold standard” of SLNB.
Materials and methods
The SentiMag technique
The SentiMag technique is a non-radioactive detection system
to magnetically mark and locate lymph nodes (LN) prior to their
surgical removal and subsequent analysis. It consists of a hand-held
magnetometer, the SentiMag, and a magnetic tracer, Siennaþ,
both CE-marked as medical devices class IIa. The tracer ﬂows
through the lymphatic system and becomes trapped in the SLNs.
Siennaþ particle dimensions (60 nm) are similar to the radiotracerD license.
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intraoperative SLN identiﬁcation.Trial design and patient recruitment
We conducted a prospective, multicentre and multinational
non-randomized paired equivalence study. From November 2012
until June 2013 we included 150 patients with histopathologically
veriﬁed breast cancer. Patient and tumour characteristics are
shown in Table 1. The study was approved by the local ethics
committees and written informed consent was obtained from all
patients. All patients planned to undergo SLNB with clinically and
ultrasonographically node-negative invasive breast carcinoma or
extended DCIS were eligible for participation in the study. Exclu-
sion criteria included allergy to iron or dextran compounds, iron
overload disease, pacemaker or ferrous metal-containing devices in
the chest wall, pregnancy and lactation. Outside these exclusion
criteria no further selection criteria were applied. The patient
cohort therefore represents typical patients encountered in normal
practice.
Axillary lymph node status was preoperatively examined by
palpation and ultrasonography with or without lymph node ﬁne
needle aspiration cytology or true cut core biopsy. In most cases the
primary tumour was located in the upper-outer quadrant (69/150,
46.0%) (see Table 1). We performed wide local excisions or quad-
rantectomy in 89.3%, oncoplastic techniques in 13.3% and modiﬁedTable 1
Patient and tumour characteristics of the 150 patients included. Results are given as
mean values or frequencies in %.
Characteristic Value
Age 57.6 y (range 29e85 y)
Height 164.7 cm (range 114e180 cm)
Weight 69.0 kg (range 46e120 kg)






Invasive carcinoma 131 (87.3%)
Ductal carcinoma in situ 19 (2.6%)
Tumour location
Upper outer quadrant 69 (46.0%)
Upper inner quadrant 28 (18.7%)
Lower inner quadrant 14 (9.3%)




















Estrogen receptor (ER)þ 134 (89.3%)
Progesterone receptor (PR)þ 125 (83.3%)
HER2 status
HER2þ 13 (8.7%)radical mastectomy and nipple-sparing mastectomy with imme-
diate reconstruction in 3.3% of the procedures.Intraoperative proceedings
SLNs were initially marked with radioisotope following a 1- or
2-day protocol as usually performed in the participating centres
(Fig. 1). The 99mTc nanocolloid in human albumin base (Nanocoll)
was injected periareolary or peritumorally and a lymphoscintig-
raphy was performed pre-operatively. After induction of general
anaesthesia, 2 ml of Siennaþ, diluted to 5 ml with physiological
saline, were injected into the subareolar interstitial tissue at least
20 min before SLNB, followed by 5 min massage to promote
migration of the magnetic tracer. No additional injection of blue
dye was performed. Before incision, count numbers of the skin, the
injection site and the axillary area (hot spots) were measured both
with the SentiMag and gamma probe. Preparation and excision of
LNs was conducted using both techniques in a strictly parallel
manner, in order to simulate routine use of both techniques. To
avoid any kind of interference with the magnetometer, polymer
retractors and forceps were used while detecting the SLNs with the
SentiMag probe. All LNs marked with either tracer were excised.
The diameter of the SentiMag probe is slightly larger (6 mm) than
that of the gamma probe, however larger incisions were not
required and SLNB could be performed via the same incision the
breast tumour was resected from, if desired. SLNs were removed
following the deﬁnition that every LN marked with either radio-
isotope or SPIO tracer is a true SLN. A LN with less than 10% of the
maximum SLN count number was deﬁned as a non-SLN for both
techniques. Therefore, SLNBwas stopped when the residual activity
in the axilla was less than 10%. SLNs and non-SLNs were submitted
separately for histopathological examination. All SLNs were
assessed intraoperatively by frozen section and postoperatively in
formalin-ﬁxed embedded sections using haematoxylin and eosin
staining.Study objectives and statistical analyses
The primary end point of the study was the proportion of suc-
cessful SLNBs (detection rate per patient) with either the standard
(radioisotope) or the magnetic (SPIO and hand-held magnetom-
eter) technique. Assuming a 97% detection rate of the standard
method [4], we deﬁned a limit difference for equivalence of 5%.
Therefore, the statistical threshold for detection rate has been
prospectively set at 92% to accept non-inferiority of the magnetic
method.
Secondary end points included the proportion of SLNs detected
(nodal detection rate) as well as the proportion of pathologically
positive results (malignancy rate) per patient and per node with
either the standard or the magnetic technique. Moreover, the
concordance and reverse concordance of successful detections (per
patient and per node; overall and in terms of malignancy) were
calculated. Concordance was deﬁned as the number of simulta-
neously radioisotope- and SPIO-positive patients or nodes, divided
by the number of patients or nodes marked by radioisotope.
Reverse concordance was deﬁned as the number of simultaneously
radioisotope and SPIO positive patients or nodes, divided by the
number of patients or nodes marked by the SPIO tracer. Only
tumour positive patients or nodes were included in the malignancy
concordance calculation. For all parameters a 95% Bayes conﬁdence
interval (CI) was calculated on the basis of binomial distribution.
Detection rate was additionally tested in a right-sided binominal
test with the alternative hypothesis that the proportion of suc-
cessful SLNBs was greater than 0.92 for each tracer. A p-value of
Fig. 1. Study workﬂow.
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calculations were performed using the R software, version 3.0.1 [6].Results
Within this study we detected 291 SLNs in 150 patients using
99mTc and Siennaþ. Mean Siennaþ migration time was
26  1 min, if the SLNB was performed ﬁrst, or 66  4 min, if breast
surgery was performed before SLNB. Data analysis led to a detec-
tion rate per patient of 97.3% (146/150; CI 93.9e99.1%; p ¼ 0.0060)
for 99mTc vs. 98.0% (147/150; CI 94.8e99.4%; p ¼ 0.0017) for
Siennaþ (Fig. 2(A)). Per patient concordance rate was 99.3% (145/
146; CI 96.8e99.9%) (Fig. 2(B)), whereas reverse per patient
concordance rate was 98.6% (145/147; CI 95.7e99.7%). An average
of 1.8 (99mTc, range: 1e9 nodes) and 1.9 (SPIO; range: 1e9 nodes)
LNs were collected per patient. Nodal detection rate was 91.8%
(267/291; CI 88.2e94.5%) for the radioisotope vs. 97.3% (283/291; CI
94.9e98.7%) for the SPIO tracer (Fig. 2(C)). Nodal concordance was
calculated as 98.5% (263/267; CI 96.5e99.5%) and reverse nodal
concordance as 92.9% (263/283; CI 89.5e95.5%).
For two patients, SLNB detection was unsuccessful with 99mTc
but successful with Siennaþ. The patients were 48 and 44 years
old, had a BMI of 21.1 and 25.3 and a tumour size of 40 mm and
29 mm, respectively. In both SLNs marked with Siennaþ macro-
metastases were found. Double SLN detection failurewas found in a
75- and an 85-year old patient with a BMI of 31.9 and 25.4 and a
tumour size of 48 mm and 15 mm, respectively. In the axillary
lymph node dissection (ALND) of the ﬁrst patient two macro-
metastases and in the second patient a histopathologically node
negative axilla were found. Another 63 year old patient with a BMI
of 28.9 and a tumour of 24 mm showed no Siennaþ and a low
radioisotope signal for 2 histopathologically negative SLNs. There-
fore, the malignancy detection rate per patient was 91.2% (31/34; CI
78.3e97.5%) for 99mTc vs. 97.1% (33/34; CI 87.1e99.7%) for the SPIO
tracer (Fig. 2(E)) and 91.1% (99mTc; 41/45; CI 80.2e96.9%) vs. 95.6%
(SPIO; 43/45; CI 86.5e99.1%) per node (Fig. 2(G)). The proportion of
histopathologically positive results was 31/146 (99mTc: 21.2%; CI
15.2e28.4%) vs. 33/147 (SPIO: 22.4%; CI 16.3e29.7%) per patient and
41/267 (99mTc: 15.4%; CI 11.4e20.0%) vs. 43/283 (SPIO: 15.2%; CI
11.4e19.7%) per node. All histopathologically positive LNs detected
with the conventional technique were also detected with the
magnetic technique, resulting in a malignancy concordance rate of
100% per patient (31/31; CI 92.3e100%) (Fig. 2(F)) and 100% per
node (41/41; CI 94.1e100%) (Fig. 2(H)). Reverse malignancy
concordance was 93.9% per patient (31/33; CI 81.9e98.7%) and
95.3% per node (41/43, CI 85.9e99.0%). No complications in termsof allergic reactions, or irritations at the injection site were
observed.Discussion
Highly accurate methods and techniques are needed to identify
SLNs correctly as well as to limit the number of false negative pa-
tients and the number of nodes in total. At present, the radiotracer/
gamma probe technique is the most accurate stand-alone method
for SLNB, which can be combined with blue dye [4]. Some inherent
disadvantages of the conventional technique led us to evaluate if
use of the SentiMag technique could improve on existing
methods. First, the radiotracer requires exposure of patient and
healthcare personnel to radiation and is not available in every
centre. Moreover, the parent isotope 99Mo is made in just a few
reactors worldwide, which has led to limited tracer availability in
the past. Secondly, the strong signal after injection around the
tumour, the so called “shine-through”, interferes with the detection
of radiation from LNs and stray radiation in the axilla quite often
disturbs the SLN detection as well. Thirdly, 99mTc has a 6 h half-life,
which limits the timeframe of SLNB. Fourthly, detection rate for
blue dye only is less than for the radiotracer alone [5], and intensive
blue dye tattoos may be seen on the breast for several months.
Fifthly, anaphylactic reactions related to blue dye can occur and
may be life-threatening [7]. Furthermore, in vitro data indicates
genotoxicity of blue dyes in the form of DNA strand breaks and
increased levels of oxidative DNA lesions [8].
In contrast to that, the SentiMag method offers advantages.
The surgeon can inject the magnetic tracer by him or herself
directly in the operation room, independent from complex time
scheduling with the nuclear medicine department (usually, no
marking on Sundays or on public holidays). Therefore, it allows a
higher number of SLNBs per day. The preparation time of 20 min is
much shorter than for the radioisotope (up to 29 h [9]) and there is
no risk of unavailability for the tracer. Surgeons proceed with
incision after obtaining a clear transcutaneous signal with the
magnetometer, without preoperative imaging. Whether preopera-
tive imaging is needed is a debatable question. Results fromvan der
Ploeg et al. [10] and Straver et al. [4] question the usefulness of
lymphoscintigraphy. Mathew et al. [11] performed re-exploration
of the axilla after SLNB and found only 3% additional lymph
nodes which were all histologically negative. Considering these
data, it might not be disadvantageous for the SentiMag technique
that a lymphoscintigraphy is missing.
Concerning detection success, the primary efﬁciency endpoint
of our study, we determined equivalency of the SentiMag
Fig. 2. Detection rates and concordance of Siennaþ and 99Tc. A Detection rate per
patient based on 150 patients. The statistical threshold for detection rate was pro-
spectively set at 92% to accept non-inferiority of the magnetic method, which is
marked by the black line in A. B Per patient concordance based on 146 patients suc-
cessfully marked with radioisotope. C Detection rate per node based on 291 isolated
SLNs. D Nodal concordance based on 267 hot nodes. E Malignancy detection rate per
patient based on 34 patients positive for malignancy. F Malignancy per patient
concordance based on 31 radioisotope positive and metastatic patients. G Malignancy
detection rate per node based on 45 histopathologically positive nodes. H Malignancy
nodal concordance based on 41 hot and malignant nodes.
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concordance of 99.3% (145/146). The statistical threshold for
detection rate had been prospectively set at 92% to accept non-
inferiority of the magnetic method, assuming a 97% detection
rate of the standard method [4]. As data analysis resulted in a
detection rate per patient of 97.3% (146/150) for 99mTc and 98.0%
(147/150) for Siennaþ, these results established with a high de-
gree of statistical probability that the SentiMag technique per-
forms equivalently well in comparison to the radiotracer method.
Additional publications concerning the performance of the mag-
netic technique for SLNB are currently limited. In an initial pilot
study SLN identiﬁcation was successful in 100% when compared to
blue dye and 99mTc [12]. Douek et al. presented their results of the
SentiMAG Multicentre Trial recently and found a detection rate of
94.4% (151/160) for the magnetic technique that was slightly lower
than our detection rate of 98.0% [13]. In agreement with our ﬁnd-
ings, Douek et al. detected slightly more SLNs with the magne-
tometer but without any signiﬁcant difference (1.9 vs. 2.0 average
per-patient-SLNs) to each technique and to the literature [10,13].
In contrast to our results, another working group used a different
magnetometer and tracer (Ferucarbotran) and found a detection
rate of only 77% [14]. Further performance evaluations, preferably
assessing independent use of magnetic and radioactive tracers,
would provide valuable information towards the efﬁcacy of mag-
netic SLNB in routine use.
Interestingly, more pathologically positive SLNs were found
with the SentiMag technique compared to the radiotracer
method, suggesting that magnetic SLNB performs equally well as
the standard method in determining malignancy. The two patients
where the SLN identiﬁcation was successful with Siennaþ but not
with the radioisotope were of younger age and had a low BMI,
whereas the two patients with SLN detection failure for both
techniques had an age >75 years and a higher BMI. The AMAROS
trial showed a similar trend for a better detection rate for younger
patients compared to older patients [4,15,16]. Following these ob-
servations, further comparative results could determine whether
the SentiMag technique might have a detection beneﬁt for
younger patients with a low BMI.
Another radiotracer-independent technique is the use of near-
infrared (NIR) ﬂuorescence imaging with indocyanine green
(ICG). With this technique SLN detection rates of 99e100% are
possible [17e22]. However, there are some limitations. First, the
short time frame for SLNB of approximately 30 min as the NIR
ﬂuorescence signal in the SLN is only visible during that time [23].
Secondly, as tissue depth is limited to about 1 cm [9,18], a high BMI
and thick subcutaneous fat tissue hampers detection. Therefore ICG
might only be useful in patients with lower BMI. Thirdly, the im-
aging equipment to show the emission of light, such as the
Fluorescence-Assisted Resection and Exploration (FLARE) imag-
ing system or the Photodynamic Eye (PDE) camera, are compara-
tively expensive and the application is more complicated [9,23].
Data concerning the use of a hybrid tracer, ICG- 99mTc-radiolabelled
nanocolloid are promising, however it is a radioactive compound
again [24].
In contrast to ICG, the SentiMag technique provides a very
comfortable timeframe. In the present study, the longest Siennaþ
migration time before SLNB lasted 160 min. Despite the long time,
SLN detection was successfully performed with the magnetometer.
Regarding patients with a high BMI we found lower transcutaneous
signals. Though, after skin incision a good signal was found in
nearly every SLN. Compared to literature [10], we removed a similar
number of SLNs (average of 1.9 SLNs) by using SentiMag. However,
with ICG the number of removed SLNs is higher (average of 3.4
SLNs) [22], which could lead to a possible higher morbidity. An
explanation might be the mapping of several SLNs, as ICG can ﬂow
M. Thill et al. / The Breast 23 (2014) 175e179 179to higher tier nodes with time passing [25]. In contrast, our results
suggest that the SPIO tracer is well retained in the “true” SLNs, as in
most cases the SLN with the highest count number was found to be
the pathologically positive SLN (SPIO: 84.8%; 28/33 vs. 99Tc: 88.0%;
27/31) for both markers if malignancy was present in the axilla of
the patient. Moreover, all patients with malignant LN involvement
would have been identiﬁed after sampling the two lymph nodes
with the highest magnetic or radioisotope count even if more LNs
were retrieved using either method, suggesting a low false negative
rate if Siennaþ is to be introduced into clinical routine as standard
method.
Conclusion
This prospective clinical study from four Central-European
centers provided convincing results, that magnetic SLNB can be
performed easily, safely and equivalently well in comparison to the
standard radioactive method. Moreover, the SentiMag technique
can be rapidly implemented into daily routine and, thanks to its
simple handling, preoperative preparation can be reduced to a
minimum. If further and consistent results prove its efﬁcacy, this
technique has the potential to become standard of care.
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